These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 20446228)
1. The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs. Novick D; Ascher-Svanum H; Zhu B; Brnabic A; Stauffer V; Peng X; Karagianis J; Perrin E Pharmacopsychiatry; 2010 May; 43(3):81-5. PubMed ID: 20446228 [TBL] [Abstract][Full Text] [Related]
2. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Soares-Weiser K; Béchard-Evans L; Lawson AH; Davis J; Ascher-Svanum H Eur Neuropsychopharmacol; 2013 Feb; 23(2):118-25. PubMed ID: 22633617 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK; Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466 [TBL] [Abstract][Full Text] [Related]
4. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Citrome L; Stroup TS Int J Clin Pract; 2006 Aug; 60(8):933-40. PubMed ID: 16893436 [TBL] [Abstract][Full Text] [Related]
5. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ; Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK; N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203 [TBL] [Abstract][Full Text] [Related]
7. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. Haro JM; Novick D; Suarez D; Roca M J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606 [TBL] [Abstract][Full Text] [Related]
8. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA; Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467 [TBL] [Abstract][Full Text] [Related]
9. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. Nasrallah HA J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522 [TBL] [Abstract][Full Text] [Related]
10. Interpreting the results of the CATIE study. Luchins DJ Psychiatr Serv; 2006 Jan; 57(1):139-40. PubMed ID: 16399979 [No Abstract] [Full Text] [Related]
11. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. Kinon BJ; Liu-Seifert H; Adams DH; Citrome L J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821 [TBL] [Abstract][Full Text] [Related]
12. What do large scale studies of medication in schizophrenia add to our management strategies? Agius M; Davis A; Gilhooley M; Chapman S; Zaman R Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774 [TBL] [Abstract][Full Text] [Related]
13. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I; J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069 [TBL] [Abstract][Full Text] [Related]
15. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. Beasley CM; Stauffer VL; Liu-Seifert H; Taylor CC; Dunayevich E; Davis JM J Clin Psychopharmacol; 2007 Jun; 27(3):252-8. PubMed ID: 17502771 [TBL] [Abstract][Full Text] [Related]